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Type 1 Diabetes (T1D) is an autoimmune disorder characterized by aberrant T cell responses. Innate
immune activation defects may facilitate a T helper 1 (Th1) phenotype. The cytokine IL-18 synergizes
with IL-12 to induce IFNg production and Th1 differentiation. The IL-18R subunit (IL18RAP) SNP rs917997
has been linked to decreased IL18RAP gene expression. Prior reports link rs917997 allele A with pro-
tection from T1D, and conversely with susceptibility to Celiac disease. However, few studies have
investigated the IL-18 pathway in T1D. In this study, we analyzed responsiveness to IL-18 in T1D, and the
effect of rs917997 genotype on IL18RAP gene expression post-activation. Upon IL-12 and IL-18 treatment,
peripheral blood mononuclear cells from subjects carrying susceptibility alleles at rs917997 produced
higher levels of IFNg than those with protective genotypes. Additionally, the SNP modiﬁed IL18RAP
surface protein expression by NK cells and gene expression in activated T cells. Taken together, these data
suggest that the disease-associated rs917997 allele G permits hyperresponsiveness to IL-18, providing a
novel target for therapeutic intervention in T1D.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Type 1 Diabetes (T1D) is a chronic autoimmune disease with a
rising incidence worldwide [1,2]. Disease onset often occurs in
childhood, resulting from a T cell mediated destruction of the
insulin-producing pancreatic b cells and a subsequent lifelong
requirement for exogenous insulin therapy [3]. Although several
recent, large-scale clinical trials aimed at preventing or curing the
disease have been conducted, few have yielded promising results
[4,5]. Therefore, it is critical that the mechanisms underlying the
autoimmune activation and b cell destruction be further elucidated,e of Medicine, Department of
J589, Gainesville, FL 32610,
Brusko), atkinson@uﬂ.edu
r Ltd. Open access under CC BY-NC-Nboth to improve biomarker monitoring in clinical trials as well as to
develop therapeutic interventions to overcome pathway defects
associated with defective immunoregulation [6].
IL-18, a member of the IL-1 superfamily of cytokines, is a
monomeric cytokine primarily produced by macrophages and
dendritic cells (DC). Like IL-1b, it is produced as an inactive pre-
cursor, pro-IL-18, then cleaved by caspase-1 into its active form. IL-
18 synergizes with IL-12 to promote the production of IFNg by
natural killer (NK) cells, T cells, and macrophages, and is custom-
arily associated with a Th1 response [7]. In addition, it can augment
Th2 and Th17 responses [8,9], and may also potentiate Treg activity
[10]. The pleiotropic nature of IL-18 has been demonstrated in the
murine non-obese diabetic (NOD) model of T1D, where early
treatment with IL-18 enhances diabetes and late administration is
preventative [11,12]. However, despite the importance of IL-18 in
regulating IFNg production and Th1 skewing, studies investigating
the IL-18 pathway in human T1D are limited.
The heterodimeric IL-18R, composed of IL-18R1 and IL-18R
accessory protein (IL-18RAP), is constitutively expressed on innate
immune system cells, while IL-18R1 is expressed onTcells. IL-18RAP
is required for signaling and is upregulated during activation,
particularly in the presence of IL-12 [13]. Recently, genome-wideD license.
Table 1
Fold change in gene expression between subjects with T1D and controls.
Gene Peripheral blood TCR stimulated Th1 polarized Th17 polarized
EBI3 0.91 (0.5260) 1.09 (0.7621) 0.90 (0.7341) 0.96 (0.9674)
GATA3 ND 1.12 (0.7623) 1.14 (0.6385) 0.82 (0.1978)
IL12A 1.08 (0.5441) 0.95 (0.2701) 0.74 (0.6830) 0.61 (0.9048)
IL12B 1.67 (0.0049) 0.85 (0.7197) 0.61 (0.1722) 0.78 (0.7802)
IL12RB1 0.83 (0.0098) 1.22 (0.6842) 1.05 (0.8940) 1.17 (0.4114)
IL12RB2 1.09 (0.3439) 1.31 (0.4359) 0.95 (0.7548) 1.44 (0.2715)
IL17A 1.86 (0.0010) ND ND ND
IL18 1.37 (0.0736) 0.57 (0.0103) 0.52 (0.0151) 0.75 (0.2647)
IL18R1 1.10 (0.427) 1.23 (0.1387) 1.10 (0.4527) 1.45 (0.0048)
IL18RAP 0.64 (0.0068) 2.28 (0.0233) 1.63 (0.0119) 1.81 (0.0751)
IL1B 0.88 (0.3157) 0.83 (0.2428) 0.75 (0.2883) 0.67 (0.3416)
IL23A 1.31 (0.2081) 0.82 (0.683) 0.74 (0.3761) 0.89 (0.6522)
IL23R 1.43 (0.0409) 1.92 (0.2263) 1.35 (0.3763) 2.84 (0.0358)
IL27A 1.61 (0.0249) ND ND ND
IL27RA 1.17 (0.1398) 0.96 (0.4813) 0.81 (0.6254) 0.79 (0.4553)
IL6 1.67 (0.0017) 1.12 (0.7708) 0.85 (0.7197) 0.84 (0.8421)
IL6R 1.24 (0.1980) ND ND ND
IL6ST 1.49 (0.0121) 1.33 (0.8534) 0.99 (0.6842) 0.95 (0.8818)
RORA4 1.11 (0.3433) 1.1 (0.7335) 1.03 (0.7335) 0.90 (0.4904)
RORC 1.17 (0.1699) 1.31 (0.2475) 0.93 (0.4359) 0.99 (0.7394)
TBX21 1.21 (0.1200) 1.43 (0.1109) 1.24 (0.0868) 1.59 (0.1296)
Data presented as fold change (P value). Peripheral blood (Paxgene) analysis cohort
consisted of 28 subjects with T1D and 23 controls. All stimulation conditions were
on a cohort of 10 subjects with T1D and 10 controls. Bold values are signiﬁcant by
Student’s t test after correction for multiple testing (Benjamini-Hochberg algo-
rithm). ND ¼ not determined. Fold change determined by dividing mean gene
expression in T1D by mean gene expression in controls.
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located on chromosome 2, as protective in T1D [14]. The SNP, a G to
A substitution in the 30 UTR of IL18RAP, has been linked to decreased
gene expression in peripheral blood [15]. However, as with many
SNPs identiﬁed in GWAS, a functional explanation for the disease
association has yet to be investigated. In this study, we determined
the effect of rs917997 genotype on stimulated IL18RAP expression,
as well as on functional responses to IL-18.
2. Materials and methods
2.1. Subjects
All study participants were consented in accordance with the
institutional review boards of the University of Florida and Nem-
ours Children’s Hospital-Orlando. Subjects did not have any overt
illnesses at the time of sample collection; control subjects did not
have any chronic diseases. Peripheral blood samples were collected
in EDTA or heparin coated vacuum tubes (BD Biosciences); basal
gene expression was analyzed from peripheral blood using PAX-
gene Blood RNA tubes (Qiagen).
2.2. PBMC stimulation
PBMC were isolated from heparinized blood by density gradient
centrifugation (Ficoll; GE Healthcare) within 20e28 h of collection.
5  105 cells/mL were cultured in 96 well round-bottom plates
(Costar) in RPMI complete media with 10% FBS (Mediatech, Inc).
PBMC were treated with 10 ng/mL IL-18, 1 ng/mL IL-12, or the
combination; supernatants were harvested at 24 h.
2.3. T cell differentiation
Naïve T cells (CD4þCD45RAþ) were isolated by negative selec-
tion from PBMC using the naïve T Cell Isolation Kit II (Miltenyi
Biotec); monocytes were enriched by selective density centrifuga-
tion (RosetteSep; Stemcell). Naive T cells and monocytes were
cultured at a 4:1 ratio in CTL media (Cellular Technology Ltd.)
supplemented with HEPES, L-glutamine, antibiotics, and 2-
mercaptoethanol at a ﬁnal concentration of 6.25  105/mL in a
96-well plate. Cells were stimulated (5 mg/mL soluble anti-CD3,
2.5 mg/mL soluble anti-CD28, and 5 ng/mL IL-2) or in the pres-
ence of Th1 (5 mg/mL anti-IL-4 and 2.5 ng/mL IL-12p70) or Th17
polarizing cytokines (10 ng/mL IL-1b, 25 ng/mL IL-6, and 5 ng/mL
TGFb) (eBioscience). RNA was isolated from total cocultured cells
after 72 h (RNAqueous Micro; Life Technologies).
2.4. ELISA
IFNg concentration was determined by a Ready-Set-Go! ELISA
kit (eBioscience). Samples were analyzed on SOFTmax PRO
(Molecular Devices).
2.5. Genotype determination
DNA was isolated from EDTA-treated peripheral blood (QIAamp
DNA Blood Mini; Qiagen). rs917997 genotype was determined by
TaqMan probe set (sequences proprietary; Life Sciences) on a
LightCycler 480 (Roche Diagnostics) as per manufacturer guidelines.
2.6. Quantitative PCR
Custom primers were designed utilizing the Universal ProbeLi-
brary (Roche Diagnostics) and NetPrimer (Premier Biosoft)
(Table 2). All primers were validated by melt curve analysis and gelelectrophoresis. Total RNA was isolated from cultured cells
(described above) or PAXgene Blood RNA Tubes (Qiagen). RNA
samples were treated with DNAse prior to cDNA generation from
250 to 500 ng RNA (SuperScript III First-Strand Synthesis SuperMix;
Life Technologies), and qPCR performed on a LightCycler 480 using
PerfeCTa SYBR Green FastMix (Quanta Biosciences). A comparative
threshold cycle (Ct) method with a cutoff of 35 cycles was used
to determine mRNA copy number relative to GAPDH. Relative
gene expression data are shown as 2DCt  103, where
DCt ¼ (CtGAPDHCtTARGET GENE).
2.7. Intracellular cytokine staining
PBMC were cultured in the presence of IL-12 and IL-18 for 24 h,
with Golgistop (BD Biosciences) added for the last 6 h of culture.
Cells were harvested, ﬁxed, permeabilized, blocked with Fc block
(eBioscience), and stained for expression of CD56, CD3, CD14 and
IFNg (Biolegend). For determination of IL18RAP expression, frozen
PBMCs were thawed and cultured as above, stained for expression
of CD3, CD56, IFNg (Biolegend), and IL18RAP (R&D Systems).
Samples were read on an LSRII Fortessa (BD Biosciences) and data
analyzed with FlowJo (Tree Star).
2.8. Statistics
Data analyses were performed in GraphPad Prism 5.1 (Graph-
Pad). Normally distributed data sets were analyzed by a 2-tailed
student’s t test or one-way ANOVA; the ManneWhitney U test
was otherwise applied. Spearman correlations were used to
determine covariable associations. In all cases, a P < 0.05 was
deemed signiﬁcant.
3. Results
3.1. rs917997 genotype modiﬁes IL18RAP gene expression
In a preliminary study, we analyzed gene expression in healthy
controls and subjects with T1D for 22 genes associated with Th1
Table 2
Quantitative PCR primers.
Gene Forward primer (50-30) Reverse primer (50-30) Amplicon length
EBI3 TGTTCTCCATGGCTCCCTAC GCTCCCTGACGCTTGTAAC 158
GAPDH ACAGTCAGCCGCATCTTCTT AATGAAGGGGTCATTGATGG 149
GATA3 GAACCGGCCCCTCATTAAG ATTTTTCGGTTTCTGGTCTGGAT 197
IL12A GAATGCAAAGCTTCTGATGGA TGGCACAGTCTCACTGTTGAA 112
IL12B AGATGGTATCACCTGGACCTTG TCCTTTGTGACAGGTGTACTGG 114
IL12RB1 TGACCCTGCAGCTCTACAAC GCCAACTTGGACACCTTGAT 70
IL12RB2 GATCTTCGTTGGTGTTGCTCCAGA CACAGTCCCCTGTTCTCCCTTCTGT 73
IL17A TCATTGGTGTCACTGCTACTGCTGC TCGTGGGATTGTGATTCCTGCC 68
IL18 CCTCCTGGCTGCCAACTCT GAAGCGATCTGGAAGGTCTGAG 100
IL18R1 AGTTATGCATATTTGAAAGGGATGT TGAGTGGATTTCATCAACAACA 62
IL18RAP CAGATATTCTGGATCCTGTCGAG TGCTTTGCAGCTAATAGTTAAAGG 74
IL1B GCTGAGGAAGATGCTGGTTC GTGATCGTACAGGTGCATCG 145
IL23A ATGATGTTCCCCATATCCAGTGTGG GCAAGCAGAACTGACTGTTGTCCCT 75
IL23R CTGAAACAGTTCCCCAGGTCACATC GCAACTGTTAGCCCAGAATTCCATG 70
IL27Aa e e 123
IL27RA GAGTTGGACCCTTGGGCGACTT CGGTACTTTTGGCTCTGGAGGTGTA 94
IL6 CAGCAAAGAGGCACTGGCAGAA GGCAAGTCTCCTCATTGAATCCAGA 95
IL6Ra e e 150
IL6ST TGCAACATTCTTACATTCGGACAGC TTTTCTGGAGGCAAGCCTGAAATTA 77
RORA4 TGTGATCGCAGCGATGAAAG ACAGTTCTTCTGACGAGGACAGG 149
RORC TGACAGAGATAGAGCACCTGGTGCA AAGATGTTGGAGCGCTGCCG 100
TBX21 TGTGACCCAGATGATTGTGCTC AGTAAAGATATGCGTGTTGGAAGC 121
Amplicon length in base pairs.
a Primers purchased from SABiosciences; proprietary sequences.
C.B. Myhr et al. / Journal of Autoimmunity 44 (2013) 8e1210and Th17 Teffector cell function, in peripheral blood and stimulated
cell culture (Table 1). In a subset of these subjects, DNA was avail-
able to retrospectively determine the effect of rs917997 genotype
on IL18RAP gene expression. In peripheral blood, IL18RAP gene
expression was signiﬁcantly lower in patients with T1D (n ¼ 21,
mean age 14.24, mean disease duration 6.51 years, 67% G/G, 28%
G/A, 5% A/A) compared to controls (n¼ 22, mean age 17.21, 50% G/G,
41% G/A, 9% A/A, P ¼ 0.0198; Fig. 1A). In both groups, the rs917997
G/G genotype corresponded to higher levels of IL18RAP expression
than the G/A genotype (P< 0.05; Fig. 1B). The rare nature of the A/A
genotype precluded its analysis, but trends continue to support a
gene dose effect. We next retrospectively determined the effect of
rs917997 genotype on naive T cell/monocyte co-cultures incubated
either with TCR stimulus alone, or in the presence of Th1 or Th17
polarizing cytokines. Subjects with T1D (n ¼ 9, mean age 19.56,
mean disease duration 8.38 years, 78% G/G, 11% G/A. 11% A/A) andFig. 1. IL18RAP gene expression is associated with rs917997 genotype. (A) Peripheral
blood IL18RAP gene expression was determined by qPCR in patients with T1D (n ¼ 21)
and controls (n ¼ 22) (P ¼ 0.0198, Student’s t test), and (B) broken down by rs917997
genotype. (C) Analysis of IL18RAP gene expression of stimulated naïve T cell:monocyte
co-cultures at 72 h in a combined T1D and control cohort (n ¼ 19). Data were
normalized to GAPDH expression  103, presented as mean  SD. *P < 0.05, Manne
Whitney U test; A/A genotype excluded from analyses.controls (n ¼ 10, mean age 19.8, 50% G/G, 40% G/A. 10% A/A) were
combined to determine the effect of the SNP on IL18RAP irre-
spective of disease state. Under TCR stimulus or Th17 polarizing
conditions, the G/G genotype (n ¼ 12) was associated with signif-
icantly higher levels of IL18RAP gene expression than the G/A ge-
notype (P < 0.05; Fig. 1C).
rs917997 allele A has previously been associated with decreased
peripheral blood IL18RAP gene expression in a large cohort of
controls as well as a cohort of subjects with celiac disease [15,16].
Observing a similar trend in T1D supports that this effect is not
signiﬁcantly altered by disease state. The SNP effect on gene
expression may be due to decreased RNA stability, for instance, by
affecting a miRNA binding site. However, lower basal IL18RAP
expression in T1D, irrespective of genotype, has not been previ-
ously reported. This discrepancywas not due to fewer subjects with
the permissive G/G genotype, as G/G was slightly enriched in the
T1D cohort (67% G/G) compared to controls (50% G/G). Though
conditions which upregulate IL18RAP have been characterized (e.g.,
IL-12 stimulation), there is little information regarding negative
regulation of the protein. Further study is needed to determine if
lower IL18RAP gene expression is caused by metabolic factors or
altered immunoregulatory mechanisms in T1D.3.2. Elevated production of IFNg in response to IL-12 and IL-18
treatment associates with rs917997 genotype
To characterize IL-18 responsiveness in T1D, we tested PBMCs
with IL-18 in vitro. Cytokine dose titrations demonstrated IL-18
synergized with low levels of IL-12 (1 ng/mL) in PBMC, leading to
robust IFNg production within 24 h (Fig. 2A). Total PBMC from
controls (closed symbols, n¼ 53, mean age 33.62, 47% G/G, 40% G/A,
13% A/A) and subjects with T1D (open symbols, 5 new onset indi-
cated by x) n ¼ 44, mean age 14.84, mean disease duration 5.21
years), 52% G/G, 43% G/A, 5% A/A) were cultured for 24 h with IL-12
(1 ng/ml) and IL-18 (10 ng/ml) (Fig. 2B). There was no signiﬁcant
difference in IFNg production in culture supernatants between T1D
and controls, and IFNg production in the T1D cohort did not
correlate with disease duration (data not shown).
We next sought to determine if rs917997 genotype had any ef-
fect on IL-12/IL-18-induced IFNg production. Analyzing the
Fig. 2. IFNg produced by NK cells in PBMC culture following IL-12 and IL-18 stimu-
lation is controlled by the IL18RAP SNP rs917997. (A) PBMC IFNg production following
stimulation by titrated doses of IL-12 and IL-18, measured by ELISA (n ¼ 2). Treatment
concentrations (bottom) expressed in ng/mL. (B) rs917997 genotype-stratiﬁed analysis
of PBMC stimulation assays from T1D (n ¼ 44, open symbols, 5 new-onset T1D indi-
cated by x) and controls (n ¼ 53, closed symbols). Cells were treated with 1 ng/mL IL-
12 and 10 ng/mL IL-18, and IFNg production measured at 24 h. (P ¼ 0.0296, One-way
ANOVA). (C) Representative ﬂow plots of stimulated PBMC from individuals with AA
(n ¼ 2) or GG (n ¼ 2) genotype after treatment with IL-12 and IL-18, gated on IFNg
positive cells. (D). Analysis of frozen PBMCs for IL18RAP expression showed AA in-
dividuals exhibited lesser frequency (left, P ¼ 0.03, t-test) and intensity (middle,
P ¼ 0.04, t-test) of IL18RAP expression on CD3-CD56þ gated NK cells, with a trend
toward lesser NK cell involvement in cytokine production for GG subjects (right).
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showed higher IFNg production in individuals with G/G compared
to G/A or A/A (Fig. 2B). Subjects with homozygous suscep-
tibility exhibited increased IFNg production (G/G, n ¼ 48,
mean  SD ¼ 10,317  12,513 pg/ml) as compared to G/A (n ¼ 40,
5687  4564 pg/ml) and A/A (n ¼ 9, 3636  2272 pg/ml) subjects
(P ¼ 0.0296, One-way ANOVA). Under these conditions, rs917997
G/G was more permissive to IL-12/IL-18-induced IFNg production,
though the majority of samples in both G/G and G/A individuals
produced moderate levels of IFNg.
It is intriguing that the production of IFNg occurred in the
absence of antigen or TCR stimulus, as previously reported [17]. We
sought to identify the cellular subset in PBMC responsible for the
observed robust IFNg production. Utilizing intracellular FACS, wewere able to identify that CD3CD56þ NK cells were a major source
of IFNg (Fig. 2C). Further analysis of frozen PBMCs of subjects ho-
mozygous at rs917997 revealed that NK cells from AA individuals
expressed signiﬁcantly reduced IL18RAP in terms of both frequency
(Fig. 2D, left, AA, n ¼ 5, mean  SD ¼ 2.01  0.75, G/G, n ¼ 5,
mean  SD ¼ 3.02  0.52, p ¼ 0.03) and intensity (Fig. 2D, middle,
AA, mean  SD ¼ 47.14  10.53, G/G, mean  SD ¼ 60.44  4.68,
p ¼ 0.04), with a trend toward lesser NK cell involvement in
cytokine production for GG subjects (Fig. 2D, right). Notably, prior
studies have reported a deﬁciency of NK cells in T1D subjects [18].
This raises the question of whether the genotype-controlled
inﬂuence noted here would impact stimulated T cells over
longer activation periods, and represents an avenue of further
investigation.
4. Discussion
These data support a novel functional effect of IL18RAP
(rs917997), and a potential mechanism for the protective effect of
the minor (A) allele in T1D. While the (A) allele has a minor pro-
tective inﬂuence in T1D (OR 0.87), it appears to confer increased
risk for celiac disease [14,19]. This opposing action may result from
alternate disease mechanisms, opposing tissue-speciﬁc inﬂuences,
or the combined inﬂuence of additional immune modulating loci.
As one example of the pleiotropic nature of this cytokine, IL-18 has
been reported to enhance murine Treg differentiation in vitro by
DCs, and increased in vivo tolerance in mice challenged with a
pathogenic bacterium [10]. The potential for opposing functions of
IL-18 in these diseases necessitates careful consideration when
investigating IL-18 pathways as possible therapeutic targets.
A potential enhanced NK cell response to IL-12 and/or IL-18
raises an intriguing possibility whereby early production of IFNg
by NK cells, prior to activation of the adaptive immune system, may
push the differentiation toward a Th1 phenotype. The prospect of
dysregulated NK cells in T1D is particularly interesting given the
large body of research investigating viral infections as environ-
mental triggers of disease [20]. In T1D, heightened responsiveness
to IL-18 in individuals with the rs917997 allele G may be one factor
leading to the break in tolerance. This is particularly true where
other susceptibility alleles may intersect with IL-18 (e.g.,
IL-12/STAT4), to augment Th1 responses. Though such alleles are
weakly associated with disease (i.e., low OR), multiple suscepti-
bility alleles may synergize to skew the immune system towards a
proinﬂammatory phenotype, creating an environment permissive
to disease pathogenesis. Such combinatorial synergism was
recently described in high-risk children who went on to develop
T1D. In this analysis, the IL18RAP susceptible SNP rs917997 was
highly represented (92%) [21]. Determining the functional effect of
disease-associated SNPs will allow us to better understand, and
potentially modify, the pathogenesis of T1D.
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